Moderna, Inc.

NasdaqGS:MRNA Rapporto sulle azioni

Cap. di mercato: US$15.8b

Moderna Gestione

Gestione criteri di controllo 3/4

Moderna Il CEO è Stephane Bancel, nominato in Oct2011, e ha un mandato di 13.08 anni. la retribuzione annua totale è $ 17.07M, composta da 9.2% di stipendio e 90.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.48% delle azioni della società, per un valore di $ 867.52M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.6 anni e 10.5 anni.

Informazioni chiave

Stephane Bancel

Amministratore delegato

US$17.1m

Compenso totale

Percentuale dello stipendio del CEO9.2%
Mandato del CEO13.1yrs
Proprietà del CEO5.5%
Durata media del management4.6yrs
Durata media del Consiglio di amministrazione10.5yrs

Aggiornamenti recenti sulla gestione

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Recent updates

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Nov 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Oct 11
The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18
Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03
Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Jul 30

Moderna: Really Strong Competition

Jun 30

Moment Of Truth Approaches For Moderna's RSV Vaccine

Jun 18

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Jun 06
What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Stephane Bancel rispetto agli utili di Moderna?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$2b

Jun 30 2024n/an/a

-US$6b

Mar 31 2024n/an/a

-US$6b

Dec 31 2023US$17mUS$2m

-US$5b

Sep 30 2023n/an/a

-US$3b

Jun 30 2023n/an/a

US$1b

Mar 31 2023n/an/a

US$5b

Dec 31 2022US$19mUS$1m

US$8b

Sep 30 2022n/an/a

US$12b

Jun 30 2022n/an/a

US$14b

Mar 31 2022n/an/a

US$15b

Dec 31 2021US$18mUS$990k

US$12b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$3b

Mar 31 2021n/an/a

US$598m

Dec 31 2020US$13mUS$946k

-US$747m

Sep 30 2020n/an/a

-US$597m

Jun 30 2020n/an/a

-US$488m

Mar 31 2020n/an/a

-US$505m

Dec 31 2019US$9mUS$921k

-US$514m

Sep 30 2019n/an/a

-US$535m

Jun 30 2019n/an/a

-US$499m

Mar 31 2019n/an/a

-US$459m

Dec 31 2018US$59mUS$863k

-US$402m

Sep 30 2018n/an/a

-US$299m

Jun 30 2018n/an/a

-US$280m

Mar 31 2018n/an/a

-US$266m

Dec 31 2017US$7mUS$651k

-US$270m

Compensazione vs Mercato: La retribuzione totale di Stephane ($USD 17.07M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 12.66M ).

Compensazione vs guadagni: La retribuzione di Stephane è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Stephane Bancel (51 yo)

13.1yrs

Mandato

US$17,068,514

Compensazione

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel served as Interim President of Valera LLC. He serves as CEO and Director at Valera LLC.Mr. Bancel serves as a S...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Stephane Bancel
CEO & Director13.1yrsUS$17.07m5.48%
$ 867.5m
Stephen Hoge
Presidentno dataUS$7.34m0.42%
$ 65.7m
James Mock
Chief Financial Officer2.2yrsUS$4.32m0.0025%
$ 390.8k
Shannon Klinger
Chief Legal Officer & Corporate Secretary3.4yrsUS$4.31m0.0047%
$ 746.7k
Jerh Collins
Chief Technical Operations & Quality Officer1.8yrsNessun datoNessun dato
Lavina Talukdar
Senior VP & Head of Investor Relations5.6yrsNessun datoNessun dato
Colleen Hussey
Senior Director of Corporate Communicationsno dataNessun datoNessun dato
Tracey Franklin
Chief People & Digital Technology Officer5.1yrsNessun datoNessun dato
Melanie Ivarsson
Chief Development Officer4.8yrsNessun datoNessun dato
Dave Johnson
Chief Data & AI Officerno dataNessun datoNessun dato
Charbel Haber
Senior VP & Head of Global Regulatory Science4.6yrsNessun datoNessun dato
Jacqueline Miller
Chief Medical Officer4.5yrsNessun datoNessun dato

4.6yrs

Durata media

49.5yo

Età media

Gestione esperta: Il team dirigenziale di MRNA è considerato esperto (durata media dell'incarico 4.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Stephane Bancel
CEO & Director13.7yrsUS$17.07m5.48%
$ 867.5m
Noubar Afeyan
Co-Founder14.8yrsUS$663.52k0.58%
$ 91.4m
Elizabeth Tallett
Independent Director4.3yrsUS$481.27k0.00018%
$ 28.5k
Robert Langer
Member of Scientific Advisory Boardno dataUS$461.27k2.99%
$ 473.1m
Scott Canute
Member of Technology Advisory Board10.5yrsNessun datoNessun dato
Elizabeth Nabel
Independent Director3.7yrsUS$476.25k0.00055%
$ 87.0k
Fred Regnier
Member of Technology Advisory Board10.5yrsNessun datoNessun dato
Francois Nader
Independent Non Executive Director4.9yrsUS$481.27k0.0054%
$ 847.9k
James Swartz
Member of Technology Advisory Board10.5yrsNessun datoNessun dato
Ulrich von Andrian-Werburg
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Jack Szostak
Chairman of Scientific Advisory Board10.5yrsNessun datoNessun dato
John Aunins
Member of Technology Advisory Board10.5yrsNessun datoNessun dato

10.5yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MRNA è composto da personale esperto e esperto (durata media dell'incarico 10.5 anni).